Flubromazolam

Flubromazolam (JYI-73) is a triazolobenzodiazepine (TBZD), which are benzodiazepine (BZD) derivatives.

Uses your system voice; voice and rate in settings.

≈ 1 min read

Cite, export and learn8 citation formats · 8 exports · lesson and quiz

Names in other languages

No names in other languages are held for this entry yet.

Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.

Flubromazolam (JYI-73) is a triazolobenzodiazepine (TBZD), which are benzodiazepine (BZD) derivatives. Flubromazolam is reputed to be highly potent, and concerns have been raised that clonazolam and flubromazolam in particular may pose comparatively higher risks than other designer benzodiazepines, due to their ability to produce strong sedation and amnesia at oral doses of as little as 0.5 mg.

Life-threatening adverse reactions have been observed at doses of only 3 mg of flubromazolam.

United States

Flubromazolam is controlled in Virginia and Wisconsin. On 23 December 2022, the DEA announced it had begun consideration on the matter of placing flubromazolam under temporary Schedule I status. Later on 25 July 2023, the DEA published a pre-print notice that flubromazolam would become temporarily scheduled as a Schedule I controlled substance from 26 July 2023 to 26 July 2025.

On July 25, 2025, and effective the following day, the DEA extended the temporary scheduling until July 26, 2026. Effective 1 April 2026, flubromazolam is permanently Schedule I under the Controlled Substances Act.

Text derived from https://en.wikipedia.org/w/index.php?oldid=1378398231 under CC BY-SA 4.0; modifications have been made.

References

1 claim could not be tied to a specific sentence and is listed in the table below instead.

    Provenance

    snapshot enwiki-001378398231 · captured 2026-10-04 · ledger · version history

    Cite this page as: encyclopegia.org, “Flubromazolam”, snapshot enwiki-001378398231. https://encyclopegia.org/a/flubromazolam